Get the Stockscreener App
0.7709
0.79%
-0.0061
After Hours:
.78
0.0091
+1.18%
Cue Biopharma Inc stock is traded at $0.7709, with a volume of 75,546.
It is down -0.79% in the last 24 hours and down -7.23% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.777
Open:
$0.765
24h Volume:
75,546
Relative Volume:
0.26
Market Cap:
$59.24M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.8471
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-2.79%
1M Performance:
-7.23%
6M Performance:
-29.92%
1Y Performance:
+35.48%
1-Day Range:
$0.765
$0.7774
1-Week Range:
$0.765
$0.81
52-Week Range:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7709 | 59.71M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Cue Biopharma Inc.’s volatility index tracking explainedProfit Target & AI Powered Market Entry Strategies - Newser
What institutional flow reveals about Cue Biopharma Inc.IPO Watch & Weekly Top Stock Performers List - Newser
Will Cue Biopharma Inc. see short term momentumMarket Trend Review & Community Verified Watchlist Alerts - Newser
A | Can Cue Biopharma, Inc. disrupt its industryJuly 2025 Spike Watch & Fast Entry and Exit Trade Plans - Lancaster City Council
What’s the profit margin of Cue Biopharma Inc.Bull Run & Weekly Momentum Stock Picks - Lancaster City Council
Sector ETF performance correlation with Cue Biopharma Inc.2025 Investor Takeaways & Weekly High Momentum Picks - Newser
What indicators show strength in Cue Biopharma Inc.Share Buyback & Real-Time Buy Signal Notifications - Newser
Cue Biopharma Inc. stock prediction for this weekEarnings Beat & High Accuracy Swing Entry Alerts - Newser
Visual trend scoring systems applied to Cue Biopharma Inc.Earnings Trend Report & High Conviction Investment Ideas - Newser
Chart based analysis of Cue Biopharma Inc. trendsInsider Buying & Breakout Confirmation Trade Signals - Newser
Published on: 2025-09-09 05:00:21 - Newser
can cue biopharma inc. rally from current levelsDollar Strength & AI Enhanced Execution Alerts - Newser
How to escape a deep drawdown in Cue Biopharma Inc.July 2025 Decliners & Weekly Market Pulse Updates - Newser
Can Cue Biopharma Inc. hit a new high this monthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
How to track smart money flows in Cue Biopharma Inc.Weekly Stock Analysis & Daily Stock Trend Reports - Newser
Intraday pattern recognizer results for Cue Biopharma Inc.CEO Change & Stock Market Timing Techniques - Newser
Regression analysis insights on Cue Biopharma Inc. performanceDividend Hike & Real-Time Stock Movement Alerts - Newser
Analyzing recovery setups for Cue Biopharma Inc. investorsQuarterly Investment Review & Entry and Exit Point Strategies - Newser
Real time pattern detection on Cue Biopharma Inc. stockWall Street Watch & Real-Time Chart Breakout Alerts - Newser
Detecting price anomalies in Cue Biopharma Inc. with AIJuly 2025 Action & Free Growth Oriented Trading Recommendations - Newser
Statistical indicators supporting Cue Biopharma Inc.’s strengthTrade Entry Report & Expert Curated Trade Setup Alerts - Newser
Why Cue Biopharma Inc. is moving todayTrade Signal Summary & Free Accurate Trade Setup Notifications - Newser
What is Cue Biopharma Inc. s 5 year growth outlookEarnings Overview Report & Weekly Chart Analysis and Trade Guides - beatles.ru
Advanced analytics toolkit walkthrough for Cue Biopharma Inc.Quarterly Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Can you recover from losses in Cue Biopharma Inc.Weekly Profit Summary & Risk Managed Investment Strategies - Newser
Technical signs of recovery in Cue Biopharma Inc.Market Activity Recap & Proven Capital Preservation Tips - Newser
Visualizing Cue Biopharma Inc. stock with heatmapsPortfolio Growth Summary & Real-Time Stock Price Movement Reports - Newser
Does Cue Biopharma Inc. meet Warren Buffett’s criteriaShare Buyback & Safe Capital Growth Stock Tips - خودرو بانک
Published on: 2025-09-06 04:00:09 - Newser
Should you avoid Cue Biopharma Inc. stock right nowJuly 2025 Trends & Weekly Watchlist for Consistent Profits - خودرو بانک
What is Cue Biopharma Inc. s revenue forecastWeekly Trend Report & Weekly Stock Breakout Alerts - خودرو بانک
Order flow analysis tools used on Cue Biopharma Inc.Weekly Gains Summary & High Conviction Trade Alerts - Newser
Fed Watch: Will Cue Biopharma Inc. outperform its industry peersEarnings Overview Report & Daily Entry Point Alerts - خودرو بانک
Key resistance and support levels for Cue Biopharma Inc.2025 Dividend Review & Risk Managed Investment Strategies - Newser
Is Cue Biopharma Inc. subject to activist investor interestMarket Movers & Verified Swing Trading Watchlists - خودرو بانک
Cue Biopharma at Cantor Conference: Strategic Focus on T-Cell Modulation - Investing.com Canada
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):